Journal of Hepatology
Volume 53, Issue 2 , Pages 230-237 , August 2010

Care of hepatitis C virus infection in human immunodeficiency virus-infected patients: Modifications in three consecutive large surveys between 2004 and 2009

  • Patrice Cacoub

      Affiliations

    • Université Pierre et Marie Curie-Paris6, CNRS, UMR 7211, France
    • AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris F-75013, France
    • Corresponding Author InformationCorresponding author. Address: AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris F-75013 France. Tel.: + 33 1 42 17 80 27; fax: + 33 1 42 17 80 33.
    • ,
  • Philippe Halfon

      Affiliations

    • Laboratoire Alphabio, Marseille, France
    • ,
  • Eric Rosenthal

      Affiliations

    • Service de Médecine Interne, Hôpital de l’Archet, Nice, France
    • ,
  • François Bailly

      Affiliations

    • Service d’Hépatogastroentérologie Hotel Dieu, Lyon, France
    • ,
  • Firouze Bani Sadr

      Affiliations

    • Service de Maladies Infectieuses, Hôpital Tenon, Paris, France
    • ,
  • Yves Benhamou

      Affiliations

    • Service d’Hépatogastroentérologie, Hôpital de la Pitié-Salpêtrière, Paris, France
    • ,
  • Stéphane Chevaliez

      Affiliations

    • Centre National de Référence des Hépatites Virales B, C et Delta, Laboratoire de Virologie et INSERM U955, Hôpital Henri Mondor, Université Paris 12, Créteil, France
    • ,
  • Jean Michel Pawlotsky

      Affiliations

    • Centre National de Référence des Hépatites Virales B, C et Delta, Laboratoire de Virologie et INSERM U955, Hôpital Henri Mondor, Université Paris 12, Créteil, France
    • ,
  • Lionel Piroth

      Affiliations

    • Service de Maladies Infectieuses, Dijon, France
    • ,
  • Yazdan Yazdanpanah

      Affiliations

    • Service de Maladies Infectieuses, Nancy, France
    • ,
  • Stanislas Pol

      Affiliations

    • Service d’Hépatologie, Hôpital Cochin, Université René Descartes Paris V and INSERM U567, Paris, France

Received 30 November 2009 ,Revised 9 February 2010 ,Accepted 15 March 2010.

References 

  1. Cacoub P, Geffray L, Rosenthal E, Perronne C, Veyssier P, Raguin G, et al. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French departments of internal medicine/infectious diseases, in 1995 and 1997. Clin Infect Dis. 2001;32:1207–1214
  2. Rosenthal E, Poirée M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS. 2003;17:1803–1809
  3. Jaggy C, von Overbeck J, Ledergerber B, Schwarz C, Egger M, Rickenbach M, et al. Mortality in the Swiss HIV cohort study (SHCS) and the Swiss general population. Lancet. 2003;362:877–878
  4. Rosenthal E, Salmon-Céron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19). HIV Med. 2009;10:282–289
  5. Macías J, Berenguer J, Japón MA, Girón JA, Rivero A, López-Cortés LF, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009 Jun 19 [Epub ahead of print].
  6. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol. 2008;48:353–367
  7. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355
  8. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. PEG-interferon-alfa-2a plus ribavirin versus interferon-alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-co-infected persons. N Engl J Med. 2004;351:451–459
  9. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon-alfa-2a plus ribavirin versus interferon-alfa-2a plus ribavirin in HIV-infected patients. N Engl J Med. 2004;351:438–450
  10. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. A randomized controlled trial of pegylated interferon alfa-2b plus ribavirin versus standard interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C in HIV-infected patients (RIBAVIC-ANRS HC02). JAMA. 2004;292:2839–2848
  11. Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, et al. Peginterferon-alfa-2b plus ribavirin versus interferon-alfa-2b plus ribavirin for treatment of HIV–HCV co-infected patients. AIDS. 2004;18:F27–F36
  12. Berenguer J, Alvarez-Pellicer J, Martín PM, López-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50:407–413
  13. Laguno M, Cifuentes C, Murillas J, Veloso S, Larrousse M, Payeras A, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology. 2009;49:22–31
  14. Righi E, Beltrame A, Bassetti M, Lindstrom V, Mazzarello G, Dentone C, et al. Therapeutical aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort. Infection. 2008;36:358–361
  15. Crespo M, Mira JA, Pineda JA, Van den Eynde E, Ríos-Villegas MJ, Collado A, et al. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen. J Antimicrob Chemother. 2008;62:793–796
  16. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis. 2003;36:97–100
  17. Cacoub P, Rosenthal E, Halfon P, Sene D, Perronne C, Pol S. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life. J Viral Hepat. 2006;13:678–682
  18. Mehta SH, Lucas GM, Mirel LB, Torbenson M, Higgins Y, Moore RD, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS. 2006;20:2361–2369
  19. Nunes D, Saitz R, Libman H, Cheng DM, Vidaver J, Samet JH. Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems. Alcohol Clin Exp Res. 2006;30:1520–1526
  20. Edlin BR, Kresina TF, Raymond DB, Carden MR, Gourevitch MN, Rich JD, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis. 2005;40:S276–S285
  21. Scheft H, Fontenette DC. Psychiatric barriers to readiness for treatment for hepatitis C Virus (HCV) infection among injection drug users: clinical experience of an addiction psychiatrist in the HIV–HCV coinfection clinic of a public health hospital. Clin Infect Dis. 2005;40:S292–S296
  22. Cacoub P, Halfon P, Rosenthal E, Pialoux G, Benhamou Y, Perronne C, et al. Treatment of hepatitis C virus in human immunodeficiency virus infected patients in “real life”: modifications in two large surveys between 2004 and 2006. J Hepatol. 2008;48:35–42
  23. Butt AA, Khan UA, Shaikh OS, McMahon D, Dorey-Stein Z, Tsevat J, et al. Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials. 2009;10:25–32
  24. McLaren M, Garber G, Cooper C. Barriers to hepatitis C virus treatment in a Canadian HIV-hepatitis C virus coinfection tertiary care clinic. Can J Gastroenterol. 2008;22:133–137
  25. Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showler G, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend. 2008;93:141–147
  26. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol. 2005;42:615–624
  27. Rockstroh J, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, et al. EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 2008;9:82–88
  28. Cacoub P, Carrat F, Bédossa P, Lambert J, Pénaranda G, Perronne C, et al. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study – ANRS HC02. J Hepatol. 2008;48:765–773
  29. Halfon P, Carrat F, Bédossa P, Lambert J, Pénaranda G, Perronne C, et al. Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the fibrovic 2 study – ANRS HC02. Antivir Ther. 2009;14:211–219
  30. de Lédinghen V, Douvin C, Kettaneh A, Ziol M, Roulot D, Marcellin P, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr. 2006;41:175–179
  31. Kirk GD, Astemborski J, Mehta SH, Spoler C, Fisher C, Allen D, et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis. 2009;48:963–972
  32. Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konaté A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005;42:1373–1381
  33. Suzman DL, McLaughlin M, Hu Z, Kleiner DE, Wood B, Lempicki RA, et al. Identification of novel markers for liver fibrosis in HIV/hepatitis C virus coinfected individuals using genomics-based approach. AIDS. 2008;22:1433–1439
  34. Tien PC. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. Am J Gastroenterol. 2005;100:2338–2354
  35. Falconer K, Sandberg JK, Reichard O, Alaeus A. HCV/HIV co-infection at a large HIV outpatient clinic in Sweden: feasibility and results of hepatitis C treatment. Scand J Infect Dis. 2009;26:1–5
  36. Maida I, Soriano V, Ramos B, Rios P, Gonzalez-Lahoz J, Nunez M. Characteristics and prospects for hepatitis C therapy of an HIV–HCV coinfected population followed at a reference HIV center. HIV Clin Trials. 2005;6:329–336
  37. Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008;33:126–133
  38. Grebely J, Raffa JD, Lai C, Krajden M, Kerr T, Fischer B, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat. 2009;16:352–358
  39. Mocroft A, Rockstroh J, Soriano V, Kirk O, Viard JP, Caplinskas S, et al. EuroSIDA Study Group. Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. Scand J Infect Dis. 2006;38:1092–1097
  40. Cooper CL, Cameron DW. Effect of alcohol use and highly active antiretroviral therapy on plasma levels of hepatitis C virus (HCV) in patients coinfected with HIV and HCV. Clin Infect Dis. 2005;41:S105–S109
  41. Novick DM, Kreek MJ. Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction. 2008;103:905–918
  42. Lang JP, Melin P, Ouzan D, Rotily M, Fontanges T, Marcellin P, et al. Peginterferon alfa-2b plus ribavirin therapy in patients with hepatitis C and psychiatric disorders: results of a cohort study. Antivir Ther, in press.
  43. Klein MB, Cooper C, Brouillette MJ, Sheehan NL, Benkelfat C, Annable L, et al. CTN194 Investigators. CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy. Contemp Clin Trials. 2008;29:617–630
  44. Bani-Sadr F, Goderel I, Penalba C, Billaud E, Doll J, Welker Y, et al. ANRS HC02 – Ribavic Study team. Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin. J Viral Hepat. 2007;14:639–644
  45. Soriano V, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, Ocampo A, et al. PRESCO Study Group. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin. Antivir Ther. 2007;12:469–476
  46. Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, et al. PROACTIVE Study Group. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology. 2004;40:1450–1458
  47. Núnez M, Camino N, Ramos B, Berdún MA, Barreiro P, Losada E, et al. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. Antivir Ther. 2005;10:657–662
  48. Piroth L, Martha B, Minello A, Grappin M, Chavanet P. Treatment of chronic hepatitis C in HIV-infected patients: from clinical trials to field practice. Scand J Infect Dis. 2008;40:561–564
  49. Bani-Sadr F, Lapidus N, Bedossa P, De Boever CM, Perronne C, Halfon P, et al. French National Agency for Research on AIDS; Viral Hepatitis-HC02-Ribavic Study Team. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. Clin Infect Dis. 2008;46:768–774
  50. Sulkowski MS, Mehta SH, Torbenson MS, Higgins Y, Brinkley SC, de Oca RM, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS. 2007;21:2209–2216
  51. Salmon-Ceron D, Rosenthal E, Lewden C, Bouteloup V, May T, Burty C, et al. ANRS EN19 Mortalité Study Group and Mortavic. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalité 2005 study. J Hepatol. 2009;50:736–745
  52. Neff GW, Shire NJ, Rudich SM. Outcomes among patients with end-stage liver disease who are coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2005;41:S50–S55
  53. Duclos-Vallée JC, Féray C, Sebagh M, Teicher E, Roque-Afonso AM, Roche B, et al. THEVIC Study Group. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2008;47:407–417
  54. Testillano M, Fernandez JR, Suarez MJ, Gastaca M, Bustamante J, Pijoan JI, et al. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center. Transplant Proc. 2009;41:1041–1043
  55. Tan-Tam C, Frassetto L, Stock P. Liver and kidney transplantation in HIV-infected patients. AIDS Rev. 2009;11:190–204
  56. Opravil M, Sasadeusz J, Cooper DA, Rockstroh JK, Clumeck N, Clotet B, et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40kDa) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr. 2008;47:36–49
  57. Valerio L, Yazdanpanah Y, Poizot-Martin I, Rosenthal E, Marimoutou C, Gastaut JA, et al. Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr. 2008;47:50–55
  58. Pineda JA, García-García JA, Aguilar-Guisado M, Ríos-Villegas MJ, Ruiz-Morales J, Rivero A, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology. 2007;46:622–630
  59. Pascual-Pareja JF, Caminoa A, Larrauri C, González-García J, Montes ML, Díez J, et al. HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C virus-coinfected patients with CD4 cell count of more than 350 cells/microl at the time of liver biopsy. AIDS. 2009;23:971–975
  60. Vispo E, Barreiro P, Pineda JA, Mira JA, Maida I, Martín-Carbonero L, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther. 2008;13:429–437
  61. Perrella A, Sbreglia C, D’Antonio A, Atripaldi L, Perrella O. Fosamprenavir treatment in a highly active antiretroviral therapy schedule induces a HCV-RNA decrease and a Th1 network boost in HIV/HCV-coinfected patients. Clin Microbiol Infect 2009 [Epub ahead of print].

PII: S0168-8278(10)00326-0

doi: 10.1016/j.jhep.2010.03.009

Journal of Hepatology
Volume 53, Issue 2 , Pages 230-237 , August 2010

Article Tools